AbbVie (ABBV)Fideuram Asset Management (Ireland) dac added to its stake +106K shares

119K

Shares reported · +106K vs prior quarter

0.49%

Disclosed portfolio weight

$25.9M

Reported value

Holdings as of

Jun 30, 2026

Filed

Jul 23, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Mar 27, 2026CongressDisclosed purchase of ABBV — reported range $15,001 - $50,000
2. May 5, 2026CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
3. May 27, 2026FDAFDA drug approval: Decnupaz
4. Jun 3, 2026Government · Federal Register noticeElite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications
5. Jun 8, 2026Government · Federal Register noticeDetermination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
6. Jun 12, 2026FDAFDA drug approval: Skyrizi
7. Jun 18, 2026Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $3.6K obligated to date
8. Jun 26, 2026FDAFDA drug approval: Skyrizi
9. Jun 26, 2026Government · Federal Register noticeDetermination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
10. Jun 29, 2026Government · Federal Register noticeDetermination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
11. Jul 1, 2026Federal contract · $3K obligatedDepartment of Defense awarded AbbVie: $3.3K obligated to date
12. Jul 6, 2026Company filing · Form 8-K · ResultsReported its results
13. Jul 6, 2026Government · Federal Register noticeEndo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
14. Jul 7, 2026Government · Federal Register noticeCertain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation; Termination of Investigation

What came next

1. Jul 31, 2026Company filing · Form 8-K · ResultsReported its results
2. Aug 14, 2026Insider · Their largest sale since 2023Officer sold ~$8.18M of ABBV shares in the open market
3. Sep 1, 2026Government · Federal Register noticeDetermination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
4. Sep 2, 2026Government · Federal Register noticeDetermination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
5. Sep 14, 2026CongressDisclosed sale of ABBV — reported range $15,001 - $50,000
6. Sep 25, 2026FDAFDA drug approval: Juvmo
7. Oct 5, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for AbbVie

For AbbVie, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports, 130 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

How this filing works

• SEC Form 13F

Other disclosures at AbbVie

• House Clerk periodic transaction reportSep 18, 2026
• SEC Form 13F-HRAug 26, 2026
• SEC Form 13F-HRAug 25, 2026
• SEC Form 4Aug 18, 2026
• SEC Form 13F-HRAug 17, 2026
• SEC Form 144Aug 14, 2026

Everything OQRO holds on this company is on its ABBV page.